1001413-01-9

Basic information

• Product Name: 1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid
• Synonyms: 1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid;1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic ac;3-Pyridinecarboxylic acid, 1-[(3,4-difluorophenyl)Methyl]-1,2-dihydro-2-oxo-;1-[(3,4-difluorophenyl)methyl]-1,2-dihydro-2-oxo-3-Pyridine carbocylic acid;1-(3,4-Difluorobenzyl)
• CAS NO: 1001413-01-9
• Molecular Formula: C₁₃H₉F₂NO₃
• Molecular Weight: 265
• Product Categories: Fluorine series
• Mol File: 1001413-01-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid(1001413-01-9)
• EPA Substance Registry System: 1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid(1001413-01-9)

Safety Data

• Hazardous Substances Data: 1001413-01-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid is used as a calcium channel blocker for the treatment of cardiovascular diseases such as hypertension and angina pectoris. Its ability to block calcium channels can help regulate blood pressure and improve blood flow to the heart, providing relief from symptoms associated with these conditions.
Used in Medicinal Chemistry Research:
1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid serves as a target for medicinal chemistry research to develop new drugs with improved efficacy and safety profiles. Its unique structure and functional groups offer opportunities for the design and synthesis of novel compounds with enhanced therapeutic properties.

Upstream product

• 1001412-63-0 C₁₅H₁₃F₂NO₃ 
• 1001414-50-1 C₁₄H₁₁F₂NO₃ 
• 41530-32-9 1,3-dimethyl 2-(3-methoxyprop-2-en-1-ylidene)propanedioate 
• 72235-53-1 3,4-difluorobenzylamine 
• 609-71-2 1,2-dihydro-2-oxonicotinic acid 
• 85118-01-0 alpha-bromo-3,4-difluorotoluene 
• 609-71-2 2-hydroxy-3-carboxypyridine 
• 133445-85-9 dimethyl [(2E)-3-methoxyprop-2-en-1-ylidene] malonate 

Downstream Products

• 1001413-68-8 C₂₁H₁₈F₂N₂O₃ 
• 1001413-86-0 1-(3,4-difluoro-benzyl)-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid (6-bromo-pyridin-2-ylmethyl)-amide trifluoroacetic acid salt 
• 1001412-05-0 3-({[1-(3,4-difluoro-benzyl)-2-oxo-1,2-dihydro-pyridine-3-carbonyl]-amino}-methyl)-phenylboronic acid 
• 1001414-27-2 1-(3,4-difluorobenzyl)-N-(3-isopropoxy-5-(1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1001414-53-4 1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carbonyl chloride 
• 1001414-70-5 C₁₅H₁₄F₂N₂O₃ 
• 1001409-50-2 (1-(3,4-difluorobenzyl)-2-oxo-N-{1(R)-2-[(2-oxo2,3-dihydro-1H-benzimidazol-5-yl)oxy]-1-phenylethyl}-1,2-dihydropyridine-3-carboxamide) 

Relevant articles and documents

Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another tools to fight glioblastoma

The phosphoinositide-dependent kinase-1 (PDK1) is one of the main components of the PI3K/Akt pathway. Also named the master kinase of the AGC family, PDK1 plays a critical role in tumorigenesis, by enhancing cell proliferation and inhibiting apoptosis, as well as in cell invasion and metastasis formation. Although there have been done huge efforts in discovering specific compounds targeting PDK1, nowadays no PDK1 inhibitor has yet entered the clinic. With the aim to pick out novel and potent PDK1 inhibitors, herein we report the design and synthesis of a new class of molecules obtained by merging the 2-oxo-indole nucleus with the 2-oxo-pyridonyl fragment, two moieties with high affinity for the PDK1 hinge region and its DFG-out binding site, respectively. To this purpose, a small series of compounds were synthesised and a tandem application of docking and Molecular Dynamic (MD) was employed to get insight into their mode of binding. The OXID-pyridonyl hybrid 8, possessing the lower IC50 (IC50 Combining double low line 112 nM), was also tested against recombinant kinases involved in the PI3K/PDK1/Akt pathway and was subjected to vitro studies to evaluate the cytotoxicity and the inhibition of tumour cell migration. All together the results let us to consider 8, as a lead compound of a new generation of PDK1 inhibitors and encourage us to further studies in this direction.

2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA

The present invention concern a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (I) in the treatment of pathologies which require a dual inhibitor of PDK1/AurA enzymes such as for instance tumours, particularly glioblastoma.

2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS INHIBITORS OF PDK1

The present invention concern a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (I) and new 2-oxo-1,2-dihydropyridine-3-carboxamide compounds of Formula (II) in the treatment of pathologies which require an inhibitor of PDK1 enzyme such as diabetes, neurodegenerative diseases such as Alzheimer's and Prion Diseases, and tumours such as breast, and pancreatic cancers and glioblastoma, particularly glioblastoma.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

1H - IMIDAZO [4, 5 - C] QUINOLINES

The present invention encompasses compounds of general formula (1), wherein the groups R1 to R7, Qa, Qb, L, n and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations containing such compounds and their use as medicaments.

PYRIDINONYL PDK1 INHIBITORS

The present invention provides pyridinonyl PDKl inhibitors and methods of treating cancer using the same.